Loading
Breast Cancer Treatment Studies / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Review
Frontiers in Oncology · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This systematic review synthesizes evidence from 10 trials on survival differences between HER2-low and HER2-positive breast cancer but does not perform meta-analysis due to heterogeneity. The findings remain descriptive: HER2-low tumors show distinct survival patterns modulated by hormone receptor status and therapy type, but no pooled effect estimates or direct comparative statistics are reported.
Systematic review with qualitative synthesis (Synthesis Without Meta-analysis, SWiM). Clinical trials and observational studies of breast cancer patients with HER2-low or HER2-positive status reporting PFS and OS outcomes.. Intervention: HER2-low breast cancer (with various targeted therapies and hormone receptor co-expression patterns). Compared with: HER2-positive breast cancer.
10 trials met inclusion criteria after screening 536 records and 180 full texts HER2-low tumors exhibit distinct survival trajectories compared to HER2-positive cohorts Survival disparities influenced by Hormone Receptor co-expression and type of targeted therapy received
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a narrative synthesis of how HER2-low and HER2-positive breast cancers differ in survival, highlighting the role of HR co-expression and therapy selection. However, the absence of meta-analytic estimates limits its ability to guide quantified risk stratification or direct treatment comparisons in individual patients.
A systematic review of 10 trials with qualitative synthesis only, reporting descriptive findings about survival disparities without meta-analytic effect sizes, confidence intervals, or quantified comparisons between HER2-low and HER2-positive cohorts.
As stated by the source record.
Quoted from the source exactly as published.
This review provides a narrative synthesis of how HER2-low and HER2-positive breast cancers differ in survival, highlighting the role of HR co-expression and therapy selection. However, the absence of meta-analytic estimates limits its ability to guide quantified risk stratification or direct treatment comparisons in individual patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background The emergence of HER2-low breast cancer as a distinct clinical entity has challenged the traditional binary classification of HER2 status. This systematic review aims to evaluate the disparities in Progression-Free Survival (PFS) and Overall Survival (OS) between HER2-low and HER2-positive breast cancer patients. Methods A systematic search was performed across PubMed, Scopus, Cochrane Library, ESMO and ASCO for studies published through January 2026. The Clinical trials and observational studies reporting Progression-Free Survival (PFS) and Overall Survival (OS) with Hazard Ratios (HR) were included. Due to significant clinical and methodological heterogeneity, a formal meta-analysis was deemed inappropriate; consequently, evidence was synthesized qualitatively following the Synthesis Without Meta-analysis (SWiM) guidelines. The protocol was prospectively registered in PROSPERO (CRD420261293004). Results A total of 536 records were identified; after removing 356 duplicates, 180 were screened, and 10 trials met the inclusion criteria. Preliminary synthesis indicates that HER2-low tumors exhibit distinct survival trajectories compared to HER2-positive cohorts, often influenced by Hormone Receptor (HR) co-expression and the type of targeted therapy received. Conclusion Understanding survival disparities is crucial for optimizing treatment sequencing in the era of antibody-drug conjugates (ADCs). Systematic review registration https://www.crd.york.ac.uk/prospero/, identifier CRD420261293004.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.